<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02163616</url>
  </required_header>
  <id_info>
    <org_study_id>3003</org_study_id>
    <nct_id>NCT02163616</nct_id>
  </id_info>
  <brief_title>Treatment of Postpartum Hemorrhage With Misoprostol: Fever Study</brief_title>
  <official_title>Treatment of Postpartum Hemorrhage With Misoprostol: Who do we Treat? Who Will Develop Fever?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gynuity Health Projects</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centro Rosarino de Estudios Perinatales</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Liverpool</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gynuity Health Projects</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to assess whether populations of women in Latin America outside Quito,&#xD;
      Ecuador are at increased risk for developing elevated body temperature above 40.0°C following&#xD;
      PPH treatment with 800mcg sublingual misoprostol. The study will be carried out in hospitals&#xD;
      representative of different regions of Latin America to explore environmental and genetic&#xD;
      hypotheses related to the occurrence of misoprostol-induced fever. Postpartum blood loss,&#xD;
      pulse and blood pressure will be systematically measured for all women enrolled to explore&#xD;
      new clinical indicators for identifying women who require clinical intervention for excessive&#xD;
      bleeding. Blood samples will be collected among women treated with misoprostol to investigate&#xD;
      genetic factors responsible for elevated body temperature induced by misoprostol.&#xD;
&#xD;
      The investigators hypothesize that rates of high fever (≥40.0°C) following misoprostol&#xD;
      treatment (800mcg given sublingually) will be variable across settings. The investigators&#xD;
      expect that the side effect profile following 800 mcg misoprostol given sublingually, in&#xD;
      particular the rates of any shivering and fever ≥38.0°C, will be comparable to previous&#xD;
      results using misoprostol for PPH.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2015</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rates of high fever (≥40.0°C)</measure>
    <time_frame>First 2 hours postpartum</time_frame>
    <description>Percentage of women with body temperature measures ≥40°C</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Side effect profile of misoprostol for PPH treatment</measure>
    <time_frame>Side effects observed for 3 hours post-treatment with misoprostol for PPH</time_frame>
    <description>Percentage of women experiencing any shivering and any fever or any other side effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptability of regimen and side effects to women</measure>
    <time_frame>Interviewed prior to hospital discharge (about 24 hours postpartum)</time_frame>
    <description>Percentage of women who rate side effects as acceptable, neutral, unacceptable, don't know</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Shock index values</measure>
    <time_frame>First hour of the puerperium</time_frame>
    <description>Pulse and blood pressure will be measured at pre-defined intervals (15, 30, 45, and 60 minutes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genetic factors responsible for elevated body temperature</measure>
    <time_frame>sample taken 24-48 hours postpartum</time_frame>
    <description>Blood samples will be collected among women enrolled and sent to the Wolfson centre for personalized medicine at the University of Liverpool for genetic analysis to investigate genetic markers associated with misoprostol-induced fever.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">635</enrollment>
  <condition>Postpartum Hemorrhage</condition>
  <arm_group>
    <arm_group_label>PPH Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>800mcg sublingual misoprostol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <description>800 mcg of sublingual misoprostol</description>
    <arm_group_label>PPH Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able and willing to give informed consent&#xD;
&#xD;
          -  Vaginal delivery&#xD;
&#xD;
          -  Postpartum hemorrhage due to suspected uterine atony&#xD;
&#xD;
          -  Able and willing to give informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known allergy to misoprostol or other prostaglandins&#xD;
&#xD;
          -  Underwent a c-section during the current delivery&#xD;
&#xD;
          -  Unable to provide informed consent due to mental impairment, distress during labor or&#xD;
             other reason&#xD;
&#xD;
          -  Unwilling and/or unable to respond to brief questionnaires or have her blood drawn&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beverly Winikoff, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gynuity Health Projects</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guillermo Carroli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro Rosarino de Estudios Perinatales</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jill Durocher</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gynuity Health Projects</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ilana Dzuba, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gynuity Health Projects</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Dr. A. Llano</name>
      <address>
        <city>Corrientes</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital J.R. Vidal</name>
      <address>
        <city>Corrientes</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <removed_countries>
    <country>Colombia</country>
    <country>Ecuador</country>
  </removed_countries>
  <link>
    <url>http://www.gynuity.org</url>
    <description>Gynuity Health Projects</description>
  </link>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>June 6, 2014</study_first_submitted>
  <study_first_submitted_qc>June 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2014</study_first_posted>
  <last_update_submitted>April 20, 2017</last_update_submitted>
  <last_update_submitted_qc>April 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary postpartum hemorrhage</keyword>
  <keyword>PPH</keyword>
  <keyword>uterine atony</keyword>
  <keyword>high fever</keyword>
  <keyword>hyperpyrexia</keyword>
  <keyword>shock index</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Postpartum Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

